- Vienna '18
- Athens 2019
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
First Author: A.Piotrowska-Gwozdz POLAND
Co Author(s): G. Mazur-Piotrowska D. Wygledowska-Promienska L. Drzyzga P. Gosciniewicz A. Piotrowska-Seweryn
Back to previous
The purpose of the study was to evaluate the effectiveness of topical bromfenac combined with intravitreal injections of bevacizumab (Avastin ) in comparison to anti-VEGF treatment alone in patients with AMD and CMO.
Department of Ophthalmology, University Hospital No. 5, Medical University of Silesia, Katowice, Poland; Private Outpatient Ophthalmology Practice, Medical Centre Tommed, Katowice, Poland
The comparative case-series study was conducted on two groups of patients with a diagnosed exudative AMD or CMO. All patients underwent a three-dose anti- VEGF therapy with the application of intravitreal injections of bevacizumab in one-month intervals. The treatment group consisted of 20 patients (20 eyes) who were additionally administered 0,09% topical bromfenac twice daily. The control group received no additional treatment ( i.e. bromfenac). Optical coherence tomography (OCT) was used in order to evaluate the clinical state by assessing the presence of retinal/subretinal fluid and central macular thickness ( CMT). Control visits of patients of both groups were undertaken in similar intervals.
The study showed that the visual acuity of all patients remained unaltered or a minimal improvement was observed. The reduction of mean central macular thickness was greater in combination treatment.
It has been found that the application of non-steroidal anti-inflammatory drug (NSAID)- bromfenac together with anti-VEGF therapy is an attractive alternative of treatment in patients with wet AMD and CMO and it may improve functional outcomes.